Derivation and validation of 10-year all-cause and cardiovascular disease mortality prediction model for middle-aged and elderly community-dwelling adults in Taiwan

Tsai-Chung Li¹,², Chia-Ing Li³,⁴, Chiu-Shong Liu³,⁴,⁵, Wen-Yuan Lin³,⁵, Chih-Hsueh Lin³,⁵, Shing-Yu Yang¹, Cheng-Chieh Lin³,⁴,⁵*

¹ Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan,
² Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan,
³ School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan,
⁴ Department of Medical Research, China Medical University Hospital, Taichung, Taiwan,
⁵ Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan

* cclin@mail.cmuh.org.tw

Abstract

Prediction model mainly focused on specific diseases, such as diabetes, hypertension, cardiovascular disease, or patients with cancer, or populations of Europe and America, thereby limiting its generalization. This study aimed to develop and validate a 10-year mortality risk score by using data from a population-representative sample of adults. Data were collected from 2,221 Taichung Community Health study participants aged ≥ 40 years. The baseline period of the study was 2004, and all participants were followed up until death or in 2016. Cox’s proportional hazards regression analyses were used to develop the prediction model. A total of 262 deaths were ascertained during the 10-year follow-up. The all-cause mortality prediction model calculated the significant risk factors, namely, age, sex, marital status, physical activity, tobacco use, estimated glomerular filtration rate, and albumin-to-creatinine ratio, among the baseline risk factors. The expanded cardiovascular disease (CVD) mortality prediction model consisted of six variables: age, sex, body mass index, heart disease plus heart disease medication use, stroke plus medication use, and ankle–brachial index. The areas under receiver operating curves of the 3-, 5- and 10-year predictive models varied between 0.97, 0.96, and 0.88 for all-cause mortality, and between 0.97, 0.98, and 0.84 for expanded CVD mortality. These mortality prediction models are valid and can be used as tools to identify the increased risk for mortality.

Introduction

During the past two decades, public health and medical care have been improved to reduce infant mortality and low-age mortality [1]. The mortality risk of middle-aged and elderly adults of the general population is greater than that of young adults, especially due to cancers,
cerebrovascular disease (CVA), diabetes, cardiovascular heart disease (CHD), and kidney disease [2]. Among these chronic diseases, CHD, CVA, diabetes, and kidney disease are considered as expanded cardiovascular diseases and are the primary causes of death worldwide [3]. CHD, CVA, diabetes, and kidney disease were the 2nd, 4th, 5th, and 9th leading causes of death in 2017, respectively, and accounted for more than 27% of total deaths in Taiwan [2].

Similar to many countries, Taiwan has progressively increased number of people aged 40 or above [4]. When the age structures of populations become less youthful, a tool to predict mortality risk for middle-aged and elderly adults becomes increasingly important for research, policy, and clinical practice. In addition, this rapid demographic change increases the costs on medical care and health systems [5]. We should focus on patients who would benefit the most from the preventive and therapeutic services to decrease costs and improve the efficiency. Prediction model shows the potential to support the evaluations of health economics for the allocation of healthcare resources and to provide insights into public health policy.

An easy-to-use risk-point system may be suitable in clinical practice and could easily calculate individual own mortality risk and monitor this risk over time. Mortality risk score can be applied broadly to help people and their primary physicians in making informed decisions by using the remaining life expectancy estimations [6–8]. Applying these risk-point systems provides better risk or prognostic reclassification value than clinical risk factors alone. However, most risk score systems for predicting overall mortality have been developed to focus in Western general population [9–17], and few studies in non-Western general population [18–21]. Three works explored the 5-year mortality risk by focusing on middle-aged or elderly adults residing in a community in Taiwan [18–20]. Two of these studies considered frailty markers [19, 20], and one considered cardiovascular/metabolic, inflammatory, and neuroendocrine markers [18]. None of them considered arterial stiffness, developed a prediction model for expanded cardiovascular mortality, and/or adopted the derived risk-score system. Two noninvasive measures of arterial stiffness, brachial–ankle pulse wave velocity (baPWV) and ankle–brachial index (ABI), were used frequently in community studies [22, 23]. The baPWV, reflecting arterial stiffness, arteriosclerosis, and atherosclerosis, is a marker of the severity of vascular damage [22]. ABI test is a quick, noninvasive way to examine the risk of peripheral artery disease (PAD), a chronic condition with narrowed or blocked arteries in the legs or arms. Arterial stiffness is an important predictor of mortality [24], and people with PAD are associated with an increased risk of CHD. Therefore, the present study aimed to develop and validate a risk-point system to predict long-term all-cause and expanded cardiovascular mortality in a community setting. In addition to traditional risk factors, arterial stiffness is included in this system.

Materials and methods

Study design and subjects

The Taichung Community Health study (TCHS), a community-based prospective cohort study, has been conducted among 2359 residents aged 40 years and above in Taichung City, Taiwan in October 2004. The sampling approach was a two-stage sampling design with a sampling rate proportional to the size within each stage. The sampling units for the first and second stages were Li (blocks of household units) and individual. The first stage had a selection probability of 0.125 for eight city districts, and 39 LIs were selected. Finally, 4280 individuals were selected at the second stage. We found 750 ineligible persons who were excluded at household visits and the number of study subjects for the listed reasons of eligibility was shown in S1 Table. A total of 2359 individuals participated, and the overall response rate was 66.83%. All participants of the TCHS were invited to partake in the study by letter and phone.
and to provide fasting blood sample. Data were collected using a standardized questionnaire via face-to-face interview and health checkup. By linking the National Registry of Death dataset, we obtained information on the individual’s death or survival and survival times. We further excluded 138 individuals with missing values of baseline variables. A total of 2,221 participants were randomly allocated into the derivation and validation sets in a 2:1 ratio. This study was conducted after obtaining approval from the Institutional Review Board of China Medical University Hospital (DMR92-IRB-144, DMR93-IRB-138 & CMUH106-REC2-143) and all methods were performed in accordance with the relevant guidelines and regulations. Each participant provided his/her written informed consent.

Measurements

**Questionnaire.** A standardized questionnaire providing sociodemographic characteristics, lifestyle behaviors, history of diseases, and medication use was utilized to collect data. The questionnaire included items about marital status, educational attainment level, income level, personal history of established hypertension, the presence of diabetes, heart diseases, stroke, hyperlipidemia, gout and cancer, current medications of anti-diabetes, hypertension, heart diseases, stroke and hyperlipidemia, smoking habits, alcohol intake, and leisure-time physical activity.

**Anthropometric measurement.** The anthropometric measurements consisted of body weight, height, body mass index (BMI), and blood pressure measurements. We measured weight in kilograms to the nearest 0.5 kg with an electronic medical scale (SECA, Hamburg, Germany) and height in meters to the nearest 0.5 cm with a fixed stadiometer (SECA). We derived BMI as weight in kilograms divided by the square of height in meters (kg/m$^2$). We classified persons with BMI $\geq 25$ kg/m$^2$ as overweight and BMI $\geq 30$ kg/m$^2$ as obese. An electronic device in a seated position (Colin, VP-1000, Japan) was used to measure the blood pressure.

**Laboratory examination.** Following a 12 h overnight fast, a blood sample was drawn from an antecubital vein in the morning and was sent for analysis within 4 h. Blood was tested by a biochemical autoanalyzer (Beckman Coluter, Lx-20, USA) with focus on low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, triglyceride, uric acid, urine albumin, and creatinine at the Clinical Laboratory Department of China Medical University Hospital. We measured the serum insulin level by a commercial ELISA kit (Diagnostic Products Corp., Los Angeles, CA, USA) and the fasting plasma glucose level by a glucose oxidase method (Astra-8, Beckman, CA, USA). The inter-assay and intra-assay coefficients of variation (CV) for insulin were 8.7% and 3.4%, respectively. We estimated insulin sensitivity by a homeostasis model assessment (HOMA-IR) equation. The inter-assay precision CV of urinary creatinine (Jaffe’s kinetic method) and albumin (colorimetyl BCP) were both $<3.0\%$. The lowest detection limits of urinary creatinine and albumin were $<884 \mu$mol/L and $<10$ g/L, respectively. We measured high sensitive C-reactive protein (hs-CRP) by a latex particle-enhanced immunoassay (TBA-200FR, Tokyo, Japan) with the inter-assay and intra-assay CVs of $<2.0\%$ and 1.9%, respectively, and a low detection limit of the assay of 0.1 mg/L.

**Pulse wave velocity and ABI.** baPWV and ABI were measured using pressure cuffs wrapped around the participant’s brachium and ankle [25]. The results of validation studies by using Pearson’s correlation coefficients and Bland–Altman plots revealed that this device has good validity and reproducibility [25–27], and the automatic non-invasive device could be a good screening tool for subclinical vascular pathology [28]. We obtained baPWV and ABI measurements using an automatic volume-plethysmographic device from PWV/ABI (PWV/ABI; Colin Co. Ltd., Komaki, Japan) while simultaneously recording the blood pressure, PWV,
an electrocardiogram, and hear sounds [25, 29]. The device reproducibility has been documented (CV = 8.4% and reproducibility coefficient = 0.98) [25]. The subjects were examined in the supine position after at least 5 min of rest. Pneumatic cuffs were placed on both the brachia and ankles with a sensor that analyzes the volume pulse form. An oscillometric pressure sensor was also used to measure the blood pressure. The electrodes of the electrocardiograph were placed on both wrists, and the cuffs were connected. The baPWV was calculated from the maximum of right PWV (right upper arm to right ankle) and left PWV (left upper arm to left ankle). High values of baPWV indicate high arteriosclerosis severity. The high baPWV value was selected as the representative baPWV for indexing atherosclerosis. ABI was derived by dividing the systolic blood pressure at the arteries near the ankle by the systolic blood pressure in the arms. Low ABI values indicate great arteriosclerosis severity. The representative ABI value for indexing atherosclerosis was examined by the low value between the right and left ABIs.

**Outcome ascertainment**

The primary outcome measure was all-cause and expanded cardiovascular death status, derived from record linkage with cause of death data in the Health and Welfare Data Science Center database. The time of follow-up began at entry date (index date) and ended up at the time of death, or on December 31, 2016. Expanded cardiovascular disease mortality was defined as cardiovascular disease (ICD-9-CM codes 390–459, ICD-10-CM codes 100–199) plus diabetes (ICD-9-CM code 250, ICD-10-CM codes E10–E14) plus kidney diseases (ICD-9-CM 580–589; ICD-10-CM N00–N29) [3].

**Statistical analysis**

The participants’ baseline characteristics were presented as frequency (percentage) and means ± standard deviations (SDs) when appropriate. We calculated the standardized effect sizes to assess the comparability of the baseline characteristics between the derivation and validation sets. Standardized effect sizes less than 0.1 indicated that the differences between the derivation and validation sets were trivial [30]. To build the prediction models, we used the multivariate Cox’s proportional hazards models. The variables with P-values from age adjustment analysis less than 0.05 were entered in multivariate analysis simultaneously. And then backward elimination approach was used to delete those variables with P-values > 0.05 one by one. Only variables with P < 0.05 could be retained in the final multivariate model. The proportionality of hazard assumption was confirmed in the final model by examining a bunch of the product terms of each independent variable with log follow-up time. This proportionality assumption was held for both all-cause and expanded CVD mortality (P-values: 0.2556 and 0.2710, respectively). We developed the 10-year mortality prediction models by using the derivation set and assessed the models’ predictive accuracy via the validation set. The survival curves were estimated by Kaplan–Meier method. The steps in the development of the predictive models are based on the Framingham heart study [31]. Mortality probabilities were estimated by the equation:

\[
\hat{p} = 1 - S_0(t) \exp \left( \sum \beta_i X_i \times \bar{X} \right),
\]

where \(S_0(t)\) is the baseline disease-free probability; \(\beta_i\) is the regression coefficient for \(X_i\); and \(\bar{X}\) is the mean level of \(X_i\). Discriminatory power was assessed by the receiver operating characteristic (ROC) curve analysis. For considering the effect of individuals who are alive may die later due to longer study follow-up, the estimate of area under curve by time-dependent ROC curve analysis was also reported. Hosmer–Lemeshow \(x^2\) tests were used to evaluate the goodness-of-fit by comparing the observed and predicted events of death. We performed 5000 times bootstrap resampling to assess the internal validation for the potential for overfitting or “optimism” [32]. We also assessed the model calibration for the
agreement between the model-predicted and observed probabilities. We calculated the intercept to evaluate whether or not the predictions are systematically too low or too high. Intercept value close to zero implies no systematic deviation in estimation of predicted probabilities. Moreover, calibration slope was estimated for extremeness of the predicted probabilities. Slope value close to one indicated no overfitting or “optimism” of a model. Statistical analysis was performed in SAS version 9.4 (SAS Institute Inc., Cary, NC). All statistical significance tests used two-tailed with P-value < 0.05.

Results

A total of 262 deaths occurred during follow-up over 10 years, and more than 29% showed expanded CVD deaths. The event rates for death and expanded CVD death as per 1000 person years were 6.04 to 7.12, 9.84, and 1.81, 1.92, 2.95 in the 3-, 5-, and 10-year periods, respectively. Distributions of the baseline characteristics in the derivation and validation sets were generally similar as shown in Table 1. Mean age was 56 years (SD of 11 years) in both sets, and the number of men was approximately 50% in the derivation and validation sets. All standardized differences of less than 0.1 indicated negligible differences between the derivation and validation sets [33].

Table 2 shows the univariate and multivariate analyses of the significant factors related to all-cause and expanded CVD mortality. In the multivariate Cox analysis, the significant factors of all-cause mortality were age (hazard ratio [HR]: 1.10, 95% confidence intervals [CIs]: 1.08–1.12), men (1.79, 1.24–2.60), single or widow (1.70, 1.20–2.41), smoking (1.84, 1.28–2.67), no leisure-time physical activity (1.61, 1.16–2.25), eGFR < 30 (mL/min/1.73m²) (3.26, 1.55–6.87), and ACR ≥ 300 (mg/g Cr) (4.44, 2.54–7.77). Significant factors for expanded CVD mortality were age (1.12, 1.09–1.16), BMI < 18.5 (kg/m²) (6.27, 2.47–15.81), heart disease plus heart disease medication use (2.57, 1.38–4.76), stroke plus medication use (2.45, 1.15–5.23), and ABI ≤ 0.9 (mm) (2.66, 1.23–5.76). Sex wasn’t significant but we entered it into final model due because sex was an important factor in literature [34]. The final risk scores based on the parameter estimates of regression coefficients are represented in Table 3. The risk predicting scores for all-cause mortality consisted of seven variables from 37 possible variables with the total score ranging from 0 to 18. The expanded CVD mortality risk score set consisted of six variables with a possible total score of 0–19. The predicted mortalities from all-causes were 0.1% to 99.9%, 0.3% to 100.0%, and 0.7% to 100.0% in the 3-, 5-, and 10-year periods, respectively. The mortalities from the expanded CVD were 0.1% to 100.0%, 0.1% to 100.0%, and 0.3% to 100.0% in the 3-, 5-, and 10-year periods, respectively, as shown in S2 Table.

The areas under receiver operating curves (AUCs) and their 95% CIs for all-cause mortality were 0.97 (0.94–0.99), 0.96 (0.94–0.98), and 0.88 (0.83–0.93) within the 3-, 5-, and 10-year periods, respectively. The AUCs for expanded CVD mortality were 0.97 (0.91–1.00), 0.98 (0.95–1.00), and 0.84 (0.75–0.93), respectively (S1 Fig). The similar results of AUCs were found by using time-dependent ROC curve analysis. They were 0.97, 0.96, and 0.90 for all-cause mortality, and 0.98, 0.98, and 0.88 for expanded CVD mortality in the 3-, 5-, and 10-year periods, respectively. In the validation set, the fitness indices for two mortality models exhibited excellent performance in the 3- and 5-year periods (AUC ≥ 0.9). The results for comparing predicted deaths with observed deaths in the validation sets were similar using the Hosmer–Lemeshow test (all P > 0.3) (S2 Fig). The 5000 bootstrap sampling was used to assess the internal validity of the mortality models and to estimate its performance in the validation set. The intercept and slope values were −0.01 and 0.94 for the calibration of the 10-year all-cause mortality, respectively, and 0.01 and 0.22 for the 10-year expanded CVD mortality, respectively.
Table 1. Baseline characteristics of the study subjects in the derivation and validation sets.

| Variables                        | Derivation set (n = 1,480) | Validation set (n = 1,480) | Standardized effect size |
|----------------------------------|----------------------------|---------------------------|--------------------------|
|                                  | MEAN±SD† or n (%)          | MEAN±SD† or n (%)         |                          |
| **Socio-demographic factors**    |                            |                           |                          |
| Age (years)                      | 56.70±11.79                | 56.48±11.09               | 0.02                     |
| Sex                              |                            |                           |                          |
| Male                             | 741 (50.07)                | 352 (47.50)               | 0.05                     |
| Female                           | 739 (49.93)                | 389 (52.50)               | -0.05                    |
| Marital status                   |                            |                           |                          |
| Single, widow                    | 246 (16.62)                | 124 (16.73)               | 0.00                     |
| Married                          | 1234 (83.38)               | 617 (83.27)               | 0.00                     |
| Educational attainment level     |                            |                           |                          |
| ≤6 years                         | 340 (22.97)                | 184 (24.83)               | -0.04                    |
| 7–12 years                       | 621 (41.96)                | 291 (39.27)               | 0.05                     |
| ≥13 years                        | 519 (35.07)                | 266 (35.90)               | -0.02                    |
| Income level (NT$)               |                            |                           |                          |
| ≤20,000                          | 320 (21.62)                | 145 (19.57)               | 0.05                     |
| 20,001–40,000                    | 386 (26.08)                | 205 (27.67)               | -0.04                    |
| 40,001–70,000                    | 424 (28.65)                | 198 (26.72)               | 0.04                     |
| >70,000                          | 350 (23.65)                | 193 (26.05)               | -0.06                    |
| Waist circumference (cm)†        | 81.35±10.11                | 81.27±9.88                | 0.01                     |
| Body mass index (kg/m²)†         | 24.29±3.36                 | 24.30±3.24                | 0.00                     |
| **Lifestyle behaviors**          |                            |                           |                          |
| Smoking                          | 241 (16.28)                | 115 (15.52)               | 0.02                     |
| Alcohol drinking                 | 357 (24.12)                | 161 (21.73)               | 0.06                     |
| Physical activity                | 1007 (68.04)               | 489 (65.99)               | 0.04                     |
| **Biomarker†**                   |                            |                           |                          |
| Systolic blood pressure (mm Hg) | 135.55±21.84               | 135.19±22.08              | 0.02                     |
| Diastolic blood pressure (mm Hg)| 78.9±12.53                 | 78.92±12.57               | 0.00                     |
| Fasting plasma glucose (mg/dL)   | 102.58±27.96               | 104.84±29.71              | -0.08                    |
| Insulin (uIU/ml)                 | 8.55±6.97                  | 8.27±6.26                 | 0.04                     |
| Total cholesterol (mg/dL)        | 202.44±36.92               | 204.15±37.56              | -0.05                    |
| Triglyceride (mg/dL)             | 120.15±98.02               | 122.94±88.55              | -0.03                    |
| High-density lipoprotein (mg/dL) | 46.22±12.61                | 45.39±12.61               | 0.07                     |
| Low-density lipoprotein (mg/dL)  | 126.85±33.33               | 128.3±33.43               | -0.04                    |
| hsCRP (mg/dL)                    | 0.25±0.59                  | 0.22±0.28                 | 0.06                     |
| Creatinine (mg/dL)               | 0.91±0.32                  | 0.89±0.28                 | 0.07                     |
| eGFR (mL/min/1.73m²)             | 85.37±19.02                | 86.24±17.66               | -0.05                    |
| ACR (mg/g Cr)                    | 33.73±170.65               | 25.65±134.45              | 0.05                     |
| Uric acid (mg/dL)                | 5.67±1.39                  | 5.70±1.48                 | -0.02                    |
| Ankle-brachial index             | 1.04±0.10                  | 1.04±0.09                 | 0.00                     |
| baPWV                             | 1639.41±448.62             | 1644.47±439.43            | -0.01                    |
| **History of disease**           |                            |                           |                          |
| Hypertension                     | 385 (26.01)                | 203 (27.40)               | -0.03                    |
| Diabetes Mellitus                | 125 (8.45)                 | 80 (10.80)                | -0.08                    |
| Heart disease                    | 208 (14.05)                | 97 (13.09)                | 0.03                     |
| Stroke                           | 64 (4.32)                  | 18 (2.43)                 | 0.10                     |
| Hyperlipidemia                   | 192 (12.97)                | 108 (14.57)               | -0.05                    |
| Gout                             | 137 (9.26)                 | 57 (7.69)                 | 0.06                     |

(Continued)
This result indicated that our prediction model had good prediction for 10-year all-cause mortality, but underestimated the 10-year CVD mortality.

As shown in Fig 1, the Kaplan–Meier survival curves for all-cause and expanded CVD mortality were plotted by the different tertile risk groups (all log-rank test, \( P < 0.001 \)). Compared with the low-risk group, the medium and high-risk groups had HR of 2.43 (95% CI 1.41–4.16) and 17.53 (11.39–26.98) for all-cause mortality and 2.03 (0.59–7.00) and 26.26 (10.58–65.15) for expanded CVD mortality, respectively.

**Discussion**

Our study developed novel prediction models consisting of renal function and arterial stiffness for all-cause mortality and expanded CVD mortality among middle-aged and elderly community-dwelling adults in Taiwan. These two mortality prediction models indicated excellent discrimination and good calibration for all-cause mortality in the validation sets. In addition, the two models are parsimony and reliable in computing an individual’s risks of overall mortality and expanded cardiovascular mortality based on the traditional risk factors and novel biomarkers of atherosclerosis. In addition, the strength of the present study is to provide a relatively long-term 10-year all-cause and expanded-cardiovascular mortality model in the form of risk-point system.

The all-cause mortality prediction models have been developed in previous studies [9–21]. However, these models reported lower C-values compared with those in our models. Our findings were consistent with some previous studies stating that both eGFR and proteinuria are key predictors for the all-cause mortality in general Chinese population [35, 36]. These two renal measures have contributed to their independent effect on mortality [35, 36] and to the leading risk factors of premature death, such as diabetes, hypertension, dyslipidemia, and obesity [37–39]. This condition results in the high ability on explaining most cases of premature death. Similarly, our predictive model also revealed that strong, independent, and graded associations were observed between all-cause mortality and two important renal function-related markers, namely, decreased GFR and increased urinary albumin excretion. These two variables were not considered simultaneously in the general population in the previous models [9–21].

---

**Table 1. (Continued)**

| Variables                      | Derivation set (n = 1,480) | Standardized effect size |
|-------------------------------|---------------------------|--------------------------|
|                               | MEAN±SD† or n (%)         | MEAN±SD† or n (%)        |
| Cancer                        | 46 (3.11)                 | 24 (3.24)                | -0.01 |
| **Medication use**            |                           |                          |
| Hypertension medications      | 293 (19.8)                | 156 (21.05)              | -0.03 |
| Anti-diabetes medications     | 94 (6.35)                 | 65 (8.77)                | -0.09 |
| Heart medications             | 128 (8.65)                | 58 (7.83)                | 0.03  |
| Stroke medications            | 46 (3.11)                 | 15 (2.02)                | 0.07  |
| Hyperlipidemia medications    | 71 (4.80)                 | 45 (6.07)                | -0.06 |
| **Outcome**                   |                           |                          |
| All-cause mortality           | 179 (12.09)               | 83 (11.20)               | 0.03  |
| Expanded CVD mortality        | 52 (3.51)                 | 26 (3.51)                | 0.00  |

†: SD = standard deviation; hsCRP: high sensitivity C-Reactive Protein; eGFR: estimated Glomerular filtration rate; ACR: albumin-to-creatinine ratio; baPWV: brachial-ankle Pulse Wave Velocity.

https://doi.org/10.1371/journal.pone.0239063.t001
Table 2. Cox model measured hazard ratio and 95% confidence intervals of all-cause and expanded CVD mortality.

| Variables                | All-cause mortality |                 | Expended CVD mortality |                 |
|--------------------------|---------------------|------------------|------------------------|------------------|
|                          | HR (95% CI)         | Age-adjusted     | Multivariate-adjusted  | Age-adjusted     | Multivariate-adjusted |
| **Socio-demographic factors** |                     |                  |                        |                  |                      |
| Age (years)              | 1.11 (1.10, 1.13)*** | 1.10 (1.08, 1.12)*** | 1.15 (1.12, 1.18)*** | 1.12 (1.09, 1.16)*** |
| Sex                      |                     |                  |                        |                  |                      |
| Female                   | 1.00                | 1.00             | 1.00                   | 1.00             |
| Male                     | 1.53 (1.09, 2.14)*  | 1.79 (1.24, 2.60)** | 1.74 (0.89, 3.37)*    | 1.93 (0.99, 3.74) |
| Marital status           |                     |                  |                        |                  |                      |
| Married                  | 1.00                | 1.00             | 1.00                   | 1.00             |
| Single, widow            | 1.42 (1.02, 1.98)*  | 1.70 (1.20, 2.41)** | 1.10 (0.59, 2.07)     |                  |
| BMI (kg/m²)              |                     |                  |                        |                  |                      |
| <18.5                    | 1.96 (1.05, 3.65)*  | 4.06 (1.66, 9.93)** | 6.27 (2.49, 15.81)**  |                  |
| 18.5–24.9                | 1.00                | 1.00             | 1.00                   | 1.00             |
| 25–29.9                  | 1.09 (0.79, 1.50)   | 1.52 (0.83, 2.80) | 1.38 (0.75, 2.57)     |                  |
| ≥30                      | 0.88 (0.43, 1.82)   | 1.46 (0.44, 4.85) | 1.41 (0.42, 4.74)     |                  |
| **Lifestyle behaviors**  |                     |                  |                        |                  |                      |
| Smoking                  |                     |                  |                        |                  |                      |
| No                       | 1.00                | 1.00             | 1.00                   | 1.00             |
| Yes                      | 2.43 (1.72, 3.44)** | 1.84 (1.28, 2.67)** | 1.73 (0.84, 3.56)     |                  |
| Physical activity        |                     |                  |                        |                  |                      |
| Yes                      | 1.00                | 1.00             | 1.00                   | 1.00             |
| No                       | 1.77 (1.29, 2.44)** | 1.61 (1.16, 2.25)** | 1.98 (1.11, 3.56)*    |                  |
| **Biomarker†**           |                     |                  |                        |                  |                      |
| Blood pressure (mmHg)    |                     |                  |                        |                  |                      |
| SBP<120 and DBP<80       | 1.00                | 1.00             | 1.00                   | 1.00             |
| SBP≥120 or DBP≥80        | 0.84 (0.52, 1.35)   | 2.21 (0.53, 9.29) |                        |                  |
| Total cholesterol (mg/dL)|                     |                  |                        |                  |                      |
| <200                     | 1.00                | 1.00             | 1.00                   | 1.00             |
| ≥200                     | 0.89 (0.66, 1.20)   | 0.84 (0.48, 1.47) |                        |                  |
| Triglyceride (mg/dL)     |                     |                  |                        |                  |                      |
| <150                     | 1.00                | 1.00             | 1.00                   | 1.00             |
| ≥150                     | 1.19 (0.85, 1.66)   | 0.90 (0.46, 1.74) |                        |                  |
| HDL (mg/dL)              |                     |                  |                        |                  |                      |
| Male: >40; female: >50   | 1.00                | 1.00             | 1.00                   | 1.00             |
| Male: ≤40; female: ≤50   | 0.92 (0.68, 1.23)   | 1.25 (0.72, 2.18) |                        |                  |
| LDL (mg/dL)              |                     |                  |                        |                  |                      |
| <110                     | 1.00                | 1.00             | 1.00                   | 1.00             |
| ≥110                     | 0.64 (0.46, 0.90)*  | 0.85 (0.44, 1.65) |                        |                  |
| eGFR (mL/min/1.73m²)     |                     |                  |                        |                  |                      |
| ≥60                      | 1.00                | 1.00             | 1.00                   | 1.00             |
| 30–59                    | 1.75 (1.22, 2.50)** | 1.39 (0.97, 2.01) | 1.72 (0.92, 3.22)     |                  |
| <30                      | 5.37 (2.63, 10.95)***| 3.26 (1.55, 6.87)**| 1.70 (0.22, 13.05)    |                  |
| ACR (mg/g Cr)            |                     |                  |                        |                  |                      |
| <30                      | 1.00                | 1.00             | 1.00                   | 1.00             |
| 30–299                   | 1.64 (1.16, 2.31)** | 1.42 (0.99, 2.03) | 1.40 (0.73, 2.68)     |                  |
| ≥300                     | 6.27 (3.7, 10.63)*** | 4.44 (2.54, 7.77)***| 9.12 (3.75, 22.19)*** |                  |

(Continued)
ABI measurement is recognized as a simple to perform, accurate, noninvasive, and inexpensive test; the test of ABI $\leq 0.90$ (mm) is a sensitive index to detect either symptomatic or asymptomatic peripheral arterial disease [40]. Notably, asymptomatic PAD is prevalent in 5.4% among Taiwanese individuals [41]. One systematic review described that low ABI has increased by more than three-fold risk of CVD death and also identified individuals at high risk of CVD mortality to allow for early interventions [23]. Our expanded CVD mortality prediction model included the generally accepted CVD risk factors and a novel predictor of ABI to improve the predictive ability of the models. However, the well-established risk factors such as cholesterol and hypertension, included to predict 10-year CVD mortality in the Framingham Score, are not included in our model [42]. The possible reason for this difference may be our study considered baPWV and histories of heart disease and stroke that may explain the effect of cholesterol and hypertension.

Table 2. (Continued)

| Variables                  | All-cause mortality | Expanded CVD mortality |
|----------------------------|---------------------|------------------------|
|                            | HR (95% CI)         | Age-adjusted           | Multivariate-adjusted |
| Hypertension               |                     |                        |
| No                         | 1.00                | 1.00                   |
| Yes                        |                     |                        |
| Hypertension medications   |                     |                        |
| No                         | 1.05 (0.59, 1.87)   | 2.76 (1.17, 6.53)*     |
| Yes                        | 1.04 (0.76, 1.44)   | 1.79 (0.99, 3.26)      |
| Diabetes Mellitus          |                     |                        |
| No                         | 1.00                | 1.00                   |
| Yes                        |                     |                        |
| DM medications             |                     |                        |
| No                         | 1.22 (0.57, 2.61)   | 1.11 (0.27, 4.61)      |
| Yes                        | 1.48 (1.00, 2.21)   | 1.41 (0.68, 2.91)      |
| Heart disease              |                     |                        |
| No                         | 1.00                | 1.00                   |
| Yes                        |                     |                        |
| Heart medications          |                     |                        |
| No                         | 1.36 (0.79, 2.33)   | 1.15 (0.35, 3.81)      |
| Yes                        | 1.31 (0.91, 1.89)   | 2.70 (1.49, 4.90)**    |
| Stroke                     |                     |                        |
| No                         | 1.51 (0.62, 3.68)   | 1.10 (0.15, 7.99)      |
| Yes                        | 1.49 (0.90, 2.46)   | 2.75 (1.34, 5.65)**    |
| Stroke medications         |                     |                        |
| No                         | 1.61 (0.98, 2.62)   | 2.55 (1.19, 5.48)*     |
| Yes                        | 1.65 (0.98, 2.62)   | 2.66 (1.23, 5.76)*     |

HR: hazard ratio; CI: confidence interval; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; eGFR: estimated Glomerular filtration rate; ACR: albumin-to-creatinine ratio.

* p < 0.05
** p < 0.01
*** p < 0.001.

https://doi.org/10.1371/journal.pone.0239063.t002
The expanded cardiovascular diseases mortality was a composite measure of cardiovascular-related mortality, i.e. measurements based on multiple items for cause of death that are cardiovascular-related. CKD has become recognized as a key independent risk factor for cardiovascular disease (CVD) [43]. It is now increasingly apparent that individuals with CKD are more likely to die from CVD than to develop end stage renal disease (ESRD). Thus, the death of cause due to renal diseases has been considered as CVD-related death. The advantage of a composite measure is that it typically results in an increase in the incidence rates of the composite endpoint, thus it increases its statistical power. Many prior studies had adopted the expanded cardiovascular diseases mortality as one of their outcome measures [39, 44–49]. In prior studies reporting prediction models in general population, only two studies provided risk function for CVD mortality [13, 19]. One had been conducted in Western population focusing on dietary quality score [13] for predicting 10-year CVD mortality with a highest c-statistic value of 0.805, and the other had been conducted in Chinese population focusing on

| Variables                  | β (SE) | p-value | Risk score | β (SE) | p-value | Risk score |
|----------------------------|--------|---------|------------|--------|---------|------------|
| Socio-demographic factors  |        |         |            |        |         |            |
| Age (years)                | 0.09 (0.01) | <0.001  | 0–9        | 0.11 (0.02) | <0.001  | 0–9        |
| Sex (male)                 | 0.58 (0.19) | 0.002  | 1          | 0.66 (0.34) | 0.05    | 1          |
| Single, widow              | 0.53 (0.18) | 0.003  | 1          |        |         |            |
| BMI (kg/m²) (ref: 18.5–24.9) |        |         |            |        |         |            |
| <18.5                      | 1.84 (0.47) | <0.001  | 3          |        |         |            |
| 25–29.9                    | 0.32 (0.32) | 0.30    | 1          |        |         |            |
| ≥30                        | 0.34 (0.62) | 0.58    | 1          |        |         |            |
| Lifestyle behaviors        |        |         |            |        |         |            |
| Smoking (ref: No)          | 0.61 (0.19) | 0.001  | 1          |        |         |            |
| Physical activity (ref: Yes)| 0.48 (0.17) | 0.005  | 1          |        |         |            |
| Biomarker†                 |        |         |            |        |         |            |
| eGFR (mL/min/1.73m²) (ref: ≥60) | 0.33 (0.19) | 0.08    | 1          | 1.18 (0.38) | 0.002  | 2          |
| <30                        |        |         |            |        |         |            |
| ACR (mg/g Cr) (ref: <30)   | 0.35 (0.18) | 0.06    | 1          | 1.49 (0.29) | <0.001  | 3          |
| ≥300                       |        |         |            |        |         |            |
| History of disease         |        |         |            |        |         |            |
| Heart disease (ref: No)    |        |         |            |        |         |            |
| No                         | 0.29 (1.03) | 0.78    | 1          |        |         |            |
| Yes                        | 0.90 (0.39) | 0.02    | 2          |        |         |            |
| Stroke (ref: No)           |        |         |            |        |         |            |
| No                         | 0.46 (0.62) | 0.46    | 1          |        |         |            |
| Yes                        | 0.94 (0.32) | 0.003  | 2          |        |         |            |
| Ankle-brachial index       |        |         |            |        |         |            |
| ≤0.9                       | 0.98 (0.39) | 0.01    | 2          |        |         |            |

β: parameter estimate; SE: standard error; eGFR: estimated Glomerular filtration rate; ACR: albumin-to-creatinine ratio.

https://doi.org/10.1371/journal.pone.0239063.t003
frailty markers for predicting 4-year CVD mortality with a c-statistic value of 0.80 [19]. Our study provided the risk score for expand CVD mortality focusing on traditional CVD risk factors along with renal function and arterial stiffness with good discriminatory power reaching as high as 0.98, 0.98, and 0.88 in the 3-, 5-, and 10-year periods.

Mortality predictive models have important implications for human and healthcare resource management. Therefore, we improved the previous Taiwanese mortality prediction models [18–21]. We also developed two novel models for all-cause and expanded CVD mortality by involving integrating new and novel biomarkers, considering long-term risk evaluation, and validating and calibrating multivariate risk models. Bootstrap sampling approach was further used to assess the internal validity of the present models based on 5000 samples. Our results showed good calibration for the present model of all-cause mortality with a mean slope close to 1.0.

Our study has several advantages. First, this study included one well-defined community-based cohort of middle-aged and elderly adults and the inclusion of powerful predictors of renal function and ABI. Second, the recruitment process followed built-in standardized protocols and instruments to ensure the high-quality of data collection. Our study has six limitations. First, the effects of time-varying predictors are not considered. Second, external validation was not performed because no external sample was available. Third, our study only considered expanded CVD mortality because TCHS was designed to explore the issues about cardiovascular risk factors. Other cause-specific mortalities were not considered because our study lacks the factors associated with other causes of death. Fourth, our study has a relatively small sample size compared with previous studies [10–12, 16, 21]. In addition, the calibration results indicated that our prediction for 10-year expanded CVD mortality was underestimated due to the small sample size although it has good predictive ability. Fifth, the generalization of this prediction model may vary with the medical care system. Our study was based on a population under a universal national health care system. Such a selection bias may limit our findings to be generalized to other medical care systems, but they may be generalizable to other populations under similar medical care system. Finally, the study subjects of derivation and

---

**Fig 1.** Kaplan-Meier survival curves for (A) all-cause and (B) expanded CVD mortality according to the low, medium, and high-risk groups.

https://doi.org/10.1371/journal.pone.0239063.g001
validation sets are both of Chinese. Thus, our study findings may not be generalized to other ethnic ancestries.

In conclusion, using Taiwan community survey and survival data, we have created two simple and applicable prediction score systems with excellent calibration and high discrimination and compared these systems with other existing models. These two risk score systems exhibit good ability to predict all-cause and expanded cardiovascular mortality risk factors in the general community population and reveal the relative importance of predictors. For individuals, hospitals, or healthcare providers, these systems could be used to obtain the estimates of 3-, 5-, and 10-year probabilities of death for planning lifestyle intervention or treatment on mortality reduction or patients’ quality of life improvement.

Supporting information

S1 Fig. Receiver operating characteristic curve (ROC) for (a) 3-year (b) 5-year (c) 10-year all-cause mortality and for (d) 3-year (e) 5-year (f) 10-year expanded CVD mortality in validation set.

S2 Fig. Predicted versus observed death numbers according to deciles of (a) 3-year (b) 5-year (c) 10-year all-cause mortality and (d) 3-year (e) 5-year (f) 10-year expanded CVD mortality in validation set.

S1 Table. The reasons for the ineligible persons.

S2 Table. 2. 3-, 5- and 10-year estimated risk for all-cause and expanded CVD mortality of each possible sum of points.

Author Contributions

Data curation: Chia-Ing Li, Chiu-Shong Liu, Wen-Yuan Lin, Chih-Hsueh Lin, Shing-Yu Yang.

Formal analysis: Tsai-Chung Li, Chia-Ing Li, Shing-Yu Yang.

Methodology: Tsai-Chung Li, Chiu-Shong Liu, Wen-Yuan Lin, Chih-Hsueh Lin, Cheng-Chieh Lin.

Project administration: Tsai-Chung Li, Cheng-Chieh Lin.

Writing – original draft: Tsai-Chung Li, Cheng-Chieh Lin.

Writing – review & editing: Tsai-Chung Li, Chia-Ing Li, Chiu-Shong Liu, Wen-Yuan Lin, Chih-Hsueh Lin, Shing-Yu Yang, Cheng-Chieh Lin.

References

1. Were WM, Daelmans B, Bhutta Z, Duke T, Bahl R, et al. (2015) Children’s health priorities and interventions. Bmj 351: h4300.

2. MOHW (2017) 2017 Statistics of Causes of Death.

3. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, et al. (2008) All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371: 2173–2182.

4. MOI (2017) Population by Sex and 5 Year Age Group for Counties and Cities.
5. Lassman D, Hartman M, Washington B, Andrews K, Catlin A (2014) US health spending trends by age and gender: selected years 2002–10. Health Aff (Millwood) 33: 815–822.

6. Damen JA, Hoot L, Schuit E, Debray TP, Collins GS, et al. (2016) Prediction models for cardiovascular disease risk in the general population: systematic review. Bmj 353: i2416.

7. Lee SJ, Boscardin WJ, Stijacic-Cenzer I, Conell-Price J, O’Brien S, et al. (2013) Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. Bmj 346: e8441.

8. Royce TJ, Hendrix LH, Stokes WA, Allen IM, Chen RC (2014) Cancer screening rates in individuals with different life expectancies. JAMA Intern Med 174: 1558–1565.

9. B OH, Gransar H, Callister T, Shaw LJ, Schulman-Marcus J, et al. (2018) Development and Validation of a Simple-to-Use Nomogram for Predicting 5-, 10-, and 15-Year Survival in Asymptomatic Adults Undergoing Coronary Artery Calcium Scoring. JACC Cardiovasc Imaging 11: 450–458.

10. Bello GA, Dumancas GG, Gennings C (2015) Development and Validation of a Clinical Risk-Assessment Tool Predictive of All-Cause Mortality. Bioinform Biol Insights 9: 1–10.

11. Deo R, Norby FL, Katz R, Sotoodehnia N, Adabag S, et al. (2016) Development and Validation of a Sudden Cardiac Death Prediction Model for the General Population. Circulation 134: 806–816.

12. Kobayashi LC, Jackson SE, Lee SJ, Wardle J, Steptoe A (2017) The development and validation of an index to predict 10-year mortality risk in a longitudinal cohort of older English adults. Age Ageing 46: 427–432.

13. Lassale C, Gunter MJ, Romaguera D, Peelen LM, Van der Schouw YT, et al. (2016) Diet Quality Scores and Prediction of All-Cause, Cardiovascular and Cancer Mortality in a Pan-European Cohort Study. PLoS One 11: e0159025.

14. Lim SS, Carnahan E, Nelson EC, Gillespie CW, Mokdad AH, et al. (2015) Validation of a new predictive risk model: measuring the impact of the major modifiable risks of death for patients and populations. Popul Health Metr 13: 27.

15. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER (2009) Index to predict 5-year mortality of community-dwelling adults aged 65 and older using data from the National Health Interview Survey. J Gen Intern Med 24: 1115–1122.

16. Suemoto CK, Ueda P, Beltran-Sanchez H, Lebrao ML, Duarte YA, et al. (2017) Development and Validation of a 10-Year Mortality Prediction Model: Meta-Analysis of Individual Participant Data From Five Cohorts of Older Adults in Developed and Developing Countries. J Gerontol A Biol Sci Med Sci 72: 410–416.

17. Turusheva A, Frolova E, Bert V, Hegendoerfer E, Degryse JM (2017) Validation of a new mortality risk prediction model for people 65 years and older in northwest Russia: The Crystal risk score. Arch Gerontol Geriatr 71: 105–114.

18. Goldman N, Glei DA (2015) Quantifying the value of biomarkers for predicting mortality. Ann Epidemiol 25: 901–906.e901-904.

19. Lee WJ, Peng LN, Chiu ST, Chen LK (2017) Physical Health Indicators Improve Prediction of Cardiovascular and All-cause Mortality among Middle-Aged and Older People: A National Population-based Study. Sci Rep 7: 40427.

20. Lin SY, Lee WJ, Chou MY, Peng LN, Chiu ST, et al. (2016) Frailty Index Predicts All-Cause Mortality for Middle-Aged and Older Taiwanese: Implications for Active-Aging Programs. PLoS One 11: e0161456.

21. Ding D, Rogers K, van der Ploeg H, Stamatakis E, Bauman AE (2015) Traditional and Emerging Lifestyle Risk Behaviors and All-Cause Mortality in Middle-Aged and Older Adults: Evidence from a Large Population-Based Australian Cohort. PloS Med 12: e1001917.

22. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, et al. (2003) Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 26: 615–622.

23. Qu B, Liu Q, Li J (2015) Systematic Review of Association Between Low Ankle-Brachial Index and All-Cause Cardiovascular, or Non-cardiovascular Mortality. Cell Biochem Biophys 73: 571–575.

24. Breithaupt-Grogler K, Belz G (1999) Epidemiology of the arterial stiffness. Pathol Biol (Paris) 47: 604–613.

25. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, et al. (2002) Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 25: 359–364.

26. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307–310.
27. Munakata M, Ito N, Nunokawa T, Yoshinaga K (2003) Utility of automated brachial ankle pulse wave velocity measurements in hypertensive patients. Am J Hypertens 16: 653–657.

28. Cortez-Cooper MY, Supak JA, Tanaka H (2003) A new device for automatic measurements of arterial stiffness and ankle-brachial index. Am J Cardiol 91: 1519–1522, a1519.

29. Tomiyama H, Yamashina A, Arai T, Hirose K, Koji Y, et al. (2003) Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12517 subjects. Atherosclerosis 166: 303–309.

30. Roumie CL, Greewy RA, Grijalva CG, Hung AM, Liu X, et al. (2014) Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. Jama 311: 2288–2296.

31. Sullivan LM, Massaro JM, D’Agostino RB, Sr. (2004) Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 23: 1631–1660.

32. Steyerberg E (2009) Clinical Prediction Models—A Practical Approach to Development, Validation, and Updating, Second Edition, Springer Series Statistics for Biology and Health. Cham: Springer.

33. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, et al. (2005) Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. Bmj 330: 960–962.

34. Franconi F, Campesi I, Colombo D, Antonini P (2019) Sex-Gender Variable: Methodological Recommendations for Increasing Scientific Value of Clinical Studies. Cells 8: 476.

35. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375: 2073–2081.

36. Wang J, Wang F, Liu S, Zhou M, Zhang L, et al. (2017) Reduced Kidney Function, Albuminuria, and Risks for All-cause and Cardiovascular Mortality in China: A Population-based Cohort Study. BMC Nephrol 18: 188.

37. Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, et al. (2014) Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 7: 75–88.

38. Lin CC, Chen CC, Kung PT, Li CI, Yang SY, et al. (2012) Joint relationship between renal function and proteinuria on mortality of patients with type 2 diabetes: the Taichung Diabetes Study. Cardiovasc Diabetol 11: 131.

39. Dachun X, Jue L, Liling Z, Yawei X, Dayi H, et al. (2010) Sensitivity and specificity of the ankle—brachial index to diagnose peripheral artery disease: a structured review. Vasc Med 15: 361–369.

40. Lin CC, Chen CC, Kung PT, Li CI, Yang SY, et al. (2012) Joint relationship between renal function and proteinuria on mortality of patients with type 2 diabetes: the Taichung Diabetes Study. Cardiovasc Diabetol 11: 131.

41. Lin CC, Chen CC, Kung PT, Li CI, Yang SY, et al. (2012) Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med 125: e419–e418.

42. Lin CC, Li CI, Liu CS, Lin WY, Lin CH, et al. (2019) Obesity paradox in associations between body mass index and diabetes-related hospitalization and mortality in patients with type 2 diabetes: Retrospective cohort studies. Diabetes Metab 45: 564–572.

43. Lin CC, Li CI, Yang SY, Liu CS, Chen CC, et al. (2012) Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med 125: e419–e418.

44. Lin CC, Li CI, Liu CS, Lin WY, Lin CH, et al. (2020) Dietary Macronutrient Intakes and Mortality among Patients with Type 2 Diabetes. Nutrients 12: 1665.

45. Wu CY, Chou YC, Huang N, Chou YJ, Hu HY, et al. (2014) Association of body mass index with all-cause and cardiovascular disease mortality in the elderly. PLoS One 9: e102589.

46. Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, et al. (2015) High Blood Pressure and All-Cause and Cardiovascular Disease Mortalities in Community-Dwelling Older Adults. Medicine (Baltimore) 94: e2160.

47. Yamashina A, Arai T, Hirose K, Koji Y, et al. (2003) Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12517 subjects. Atherosclerosis 166: 303–309.

48. Roumie CL, Greewy RA, Grijalva CG, Hung AM, Liu X, et al. (2014) Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. Jama 311: 2288–2296.

49. Sullivan LM, Massaro JM, D’Agostino RB, Sr. (2004) Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 23: 1631–1660.